# A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis

> **NCT03219437** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 104 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** risankizumab
- **DRUG:** methotrexate

## Key facts

- **NCT ID:** NCT03219437
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-30
- **Primary completion:** 2021-11-26
- **Final completion:** 2021-11-26
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2022-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03219437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03219437, "A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03219437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*